Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 390; číslo 4; s. 301 - 313
Hlavní autoři:	Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 25.01.2024
Témata:	Adverse events Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone marrow Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Cancer therapies CD38 antigen Death Dexamethasone Dexamethasone - administration & dosage Dexamethasone - adverse effects Disease Progression Hematology Humans Immunotherapy Induction therapy Inhibitor drugs Lenalidomide - administration & dosage Lenalidomide - adverse effects Leukemia Lymphoma Minimal residual disease Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Neutropenia Oncology Risk assessment Survival Targeted cancer therapy Thrombocytopenia Transplantation Treatments in Oncology
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2312054